The diabetes drug in TikTok for weight loss being disturbed by doctors

Videos under the hashtag #Ozempic have about 600 million views on TikTok, where many users regularly publish images of their weight loss.

The loss of 40 kilos in later than three months is possible” thanks to Ozempic, writes in the French TikTok-er in his December post with about 50 thousand views, AFP writes, conveys Klankosova.tv.

The drug for injection by Danish pharmaceutical firm “Novo Nordisk” was originally developed and approved in many countries to deal with Type 2 diabetes.

The active component of the drug, semaglutide, is linked to the receptors of a hormone that controls blood sugar, stimulating the release of insulin when glucose levels are high.

Early in 2021, surveying by colleagues revealed that almost three quarters of people using the drug lost more than 10 percent of their body weight.

“Novo Nordisk” has since developed a drug semaglutide with a higher dose called Wegovy specifically for handling obesity, which was approved for use in the United States in 2021, and in Europe and the United Kingdom in the past year.

Wegovy is not yet on the market in the United Kingdom, France or some other country, but Omeptic is available with a normal recipe.

Douglas Teenefour, head of care at the Centre “Dibets UK”, said on the charity website that Ozempic “is not a drug for people who do not have diabetes or are at risk of Type 2” diabetes.

French drug regulator ANEM has asked doctors to describe Ozempic for diabetes only.

There has been no unexpected subx0 consumer achievement in recent months”, ANSM said, adding that there were “tensions of supply” worldwide.

“Novo Nordisk” told AFP that “stronger than expected” for Ozempic had resulted in a “permanent availability and periodic reserve” worldwide.

Doctors have expressed concern that people with diabetes may not be able to assume semaglutide because of increased demand from people seeking to lose weight.

Karina Clement, an obesity specialist at the Institute of Medical Research I NSER of France said that when Wegovy becomes available, it is important that people follow their recipe closely.

It's not a magic drug,” she said. “As is always the case with obesity, it should be associated with a comprehensive treatment plan. ”

Doctors have also expressed concerns about the side effects of the semaglutide, which Faillie said were not discussed.

Neither patients nor doctors are motivated to report” side effects, he said.

But Faillie said that “also exists the rarest and most serious risks, such as the acute pancreat, which can occur even at lower doses of anthrax and rare cases of serious constremous that can lead to intestines. ”

It also pointed to a <x0 risk loss of thyroid cancer” after several years of treatment.

While the risks were reasonable considering the benefits for people with diabetes, “still has uncertainty, especially in obese patients over the long term,” she said.

If used to lose several pounds, then therapeutic profit is zero. This would simply be cosmetic, while risks remain”, Faillie added.